169, Harrison avenue Boston, MA 02111.
+1 857-302-4704

Elderly Population is Leading Development in the Global Diabetes Drugs Market

One of the crucial factors, enhancing the risk of developing prediabetes and diabetes is age. A visible up-gradation in the geriatric population has been witnessed across the globe for several decades and is estimated that the trend will be constant also in future. The average life expectancy and prevailing incidences of diabetes are majorly influencing the demand of the global diabetes drugs market. Amid the elderly population, the most growing risk is type 2 diabetes. Moreover, a large pool of the recently diagnosed diabetics is from the elderly age group.
 Below highlighted are key statistical facts to the most recent data:
• Based on 2014 GUS data, around 15% of the Poland population are older than 65 years; when compared to 1989, which accounted for only 10% of the population.
• As per the International Diabetes Federation (IDF), the number of people suffering from diabetes across the globe has reached 425 million in 2017 and is further expected to reach 629 million by 2045.
• As per IDF estimation in 2017, there are around 1.1 million children and adolescents around the world have Type 1 diabetes.
• The US Centers for Disease Control and Prevention (CDC) National Diabetes Report Statistics 2017 states that a total of 30.3 million Americans had diabetes in 2015, which represents one in 10 of the total US population. Also, in the same year, an estimate of 1.5 million new cases of diabetes was diagnosed among US adults aged 18 years or older.
• In Europe, the population of people aged 80 and above is projected to be doubled between 2013 and 2040.
A number of physiological alteration are witnessed within the older age patient body. Thus, the classic symptoms of the disease may not be expected to exhibit. Changes due to age can mask those spots. However, some considerable crucial factors leading to type 1 and type 2 diabetes are:
• Increased thirst
• Unexplained weight loss
• Fatigue
• Irritability
• Frequent infections, such as gums or skin infections and vaginal infections
• Blurred vision
• Frequent urination
• Slow-healing sores
The treatment and diagnosis of diabetes among the older adults demands for flexibility and customized approach. This group of population is heterogeneous in nature, varying in terms of life expectancy, will power to control the blood glucose, concomitant of chronic diseases and intake of injection. Also, older adults with long-term diabetes, together with several other chronic complications, require a liberal methodology to counter specific goals in the treatment.
Elderly populace suffering from diabetes is highly exposed to other chronic complications such as Dementia and Alzheimer’s, CVDs, Frailty syndrome, damage to the eyes, kidney failure, foot ulcers. Therefore, during the treatment, it is essential to consider the side effects of the medications as well as drug interactions.
 Few of the most common drugs applicable to the treatment of type 2 diabetes in the older age group are:
Sulphonylureas – is an oral medication that helps in controlling the sugar levels in the patient’s blood with type 2 diabetes. It stimulates insulin production in the pancreas and enhances the efficacy of insulin in the body.
Metformin – is of the biguanide class; it is an antihyperglycemic agent used for the treatment of type II diabetes. Currently, it is the choicest drug adopted for the management of type II diabetes and is prescribed worldwide.
Glucagon-like peptide-1 analogues – is indicated to assist other treatments in the management of type 2 diabetes. Usually, they are prescribed once on a daily basis (liraglutide) or twice by subcutaneous injection.
Gliptins – is the first agent of sitagliptin, approved by the FDA in 2006. They are majorly utilized in treating diabetes mellitus type 2 by blocking the enzyme dipeptidyl peptidase-4 (DPP-4)
Flozins – a sodium-glucose transport protein 2 inhibitor, is a type 2 diabetes medication. It reabsorbs the glucose in the kidney and lowers the sugar level in the blood.
Thiazolidinediones – also referred to glitazones, is a group of oral anti-diabetic drugs that is designed as a remedy for type 2 diabetes patients.
Insulin – Insulin therapy is a medication used in both the types – 1 and 2 of diabetes. Insulin helps in regulating the sugar levels in the blood and also stores excess glucose for energy.
Top manufacturers in the diabetes drug market such as Sanofi, Novo Nordisk A/S, AstraZeneca, Merck and Eli Lilly And Company are heavily investing in developing a pipeline of innovative drugs to discourse the unmet needs of the patients. The market is interpreting investment activities as a capacity expansion plan and rigorous R & D, which is aiming to obtain maximum growth opportunities in the coming years. This will further intensify the competition with a direct positive effect on the advent of new drugs, product extensions, new applications of the products and services.

Inkwood Research

Author: Inkwood Research

We at Inkwood research provide you with not just consulting services but also with syndicated and customized research reports which help advance your business further.
Like
Like Love Haha Wow Sad Angry

Related Posts

Leave a comment